GERMANTOWN, Md.— Senseonics Holdings, Inc. announced today an agreement with Companion Medical, Inc. to integrate Senseonics’ Eversense continuous glucose monitoring (CGM) system with Companion Medical’s InPen smart system for insulin delivery.
“There is a strong desire from people living with diabetes to have a complete picture of their real-time glucose values, rate of change and insulin information in one place so they can make better diabetes management decisions,” said Tim Goodnow, Ph.D., president and chief executive officer of Senseonics. “By partnering with Companion Medical, multiple daily injection patients using the InPen System will be able to take full advantage of the convenience of insightful and comprehensive insulin data integrated with their Eversense CGM data, giving them a more complete picture and meaningful information at their fingertips.”
The Eversense CGM System consists of a fluorescence-based sensor, a smart transmitter worn over the sensor to facilitate data communication and a mobile app for displaying glucose values, trends and alerts. The system is also reportedly first to feature a smart transmitter that provides wearers with discreet on-body vibratory alerts for high and low glucose. The transmitter can be removed, recharged and re-attached to the skin without discarding the sensor. The sensor is inserted subcutaneously in the upper arm by a health care provider via a brief in-office procedure.
Companion Medical’s InPen system is a Bluetooth-enabled smart insulin pen that automatically tracks every dose, and an integrated diabetes management app that helps patients make more informed decisions about when and how much rapid-acting insulin to take. The app includes a dose calculator to help calculate rapid-acting doses, tracks insulin-on-board to help minimize risks of insulin stacking, offers dose reminders to minimize missed doses, provides an integrated automatic logbook, allows BG meter data integration and now will include real-time Eversense CGM data. Healthcare providers are easily able to access all their patients’ data via the shareable reports to inform therapy adjustments.
“CGM has revolutionized glucose monitoring and InPen has revolutionized MDI therapy. Together this is going to be a new world for those of us who manage our diabetes with MDI. Combining these technologies is a real game-changer. At Companion Medical our mission is to create affordable, easy-to-use solutions that allow people with insulin-dependent diabetes to focus more on their lives and less on their condition and the team at Senseonics is a great partner with a similar vision,” added Companion Medical’s chief executive officer Sean Saint. “We are excited about what our partnership with Senseonics will bring to those living with diabetes, their healthcare teams, payers and the smart pen category overall.”